A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer.

Trial Profile

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Advanced breast cancer; Bone metastases; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Dec 2015 Results of a post hoc analysis presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 30 May 2014 Subgroup analysis results for primary endpoint (time to SRE) published in the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Sep 2012 Results of a pooled analysis of this and 2 other randomised trials in a total of 5723 patients (including the 2046 patients from this trial) published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top